|
 |
|
|||||||
|
|||||||||
Eur Respir J 2007, doi:10.1183/09031936.00128806
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL ARTICLE |
Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD
1 Dept of Respiratory Medicine and Allergology, Lund University, Lund, Sweden
2 Dept of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 Dept of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UK
4 Dept of Respiratory Diseases, National Hospital Rikshospitalet, University of Oslo, Oslo, Norway
5 AstraZeneca R&D, Lund, Sweden
* To whom correspondence should be addressed. E-mail: claes-goran.lofdahl{at}med.lu.se.
 |
Abstract |
|---|
Epidemiological studies have indicated that chronic obstructive pulmonary disease (COPD) may be associated with an increased incidence of ischaemic cardiac events.
We performed a post-hoc analysis of the EUROSCOP study - a 3-year, placebo-controlled study of an inhaled corticosteroid budesonide 800 µg·day-1 in smokers (mean age 52 years) with mild COPD. We evaluated whether long-term budesonide treatment attenuates the incidence of ischaemic cardiac events, including angina pectoris, myocardial infarction, coronary artery disorder and myocardial ischaemia.
Among the 1175 patients evaluated for safety, 49 patients (4.2%) experienced 60 ischaemic cardiac events. Patients treated with budesonide had a significantly lower incidence of ischaemic cardiac events (18 out of 593; 3.0%) than those receiving placebo (31 out of 582; 5.3%; p<0.05).
These results support the hypothesis that treatment with inhaled budesonide reduces ischaemic cardiac events in patients with mild COPD.
Keywords: Budesonide, COPD, ischaemic cardiac events
This article has been cited by other articles:
|
|
 |
|
  S.F. P. Man, Xuekui Zhang, R. Vessey, T. Walker, K. Lee, D. Park, and D. D. Sin The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study Therapeutic Advances in Respiratory Disease, April 1, 2009; 3(2): 73 - 80. [Abstract] [PDF]
|
|
|
|
|
|
M. Cazzola From large clinical trials to management of COPD in the real world Therapeutic Advances in Respiratory Disease, February 1, 2009; 3(1): 39 - 46. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Gerhardsson de Verdier The Big Three Concept: A Way to Tackle the Health Care Crisis? Proceedings of the ATS, December 1, 2008; 5(8): 800 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Camargo Jr, R. G. Barr, R. Chen, and F. E. Speizer Prospective Study of Inhaled Corticosteroid Use, Cardiovascular Mortality, and All-Cause Mortality in Asthmatic Women Chest, September 1, 2008; 134(3): 546 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Mendes, G. Horvath, P. Rebolledo, M. E. Monzon, S. M. Casalino-Matsuda, and A. Wanner Effect of an inhaled glucocorticoid on endothelial function in healthy smokers J Appl Physiol, July 1, 2008; 105(1): 54 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. MacNee Update in Chronic Obstructive Pulmonary Disease 2007 Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |